Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer

ClinicalTrials.gov ID: NCT00410826

Public ClinicalTrials.gov record NCT00410826. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck

Study identification

NCT ID: NCT00410826
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: University of Washington; Other
Enrollment: 204 participants

Conditions and interventions

Conditions

Interventions

erlotinib hydrochloride Drug
cisplatin Drug
3-dimensional conformal radiation therapy Radiation
intensity-modulated radiation therapy Radiation
quality-of-life assessment Procedure

Drug · Radiation · Procedure

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2006
Primary completion: Apr 30, 2012
Completion: Not listed
Last update posted: May 9, 2013

Started 2006

United States locations

U.S. sites: 9
U.S. states: 7
U.S. cities: 9

Facility	City	State	ZIP	Site status
Alaska Oncology and Hematology LLC	Anchorage	Alaska	99508	—
University of Miami Miller School of Medicine-Sylvester Cancer Center	Miami	Florida	33136	—
University of New Mexico Health Science CCOP	Albuquerque	New Mexico	87131	—
University of North Carolina	Chapel Hill	North Carolina	27599	—
New Hanover Radiation Oncology Center	Wilmington	North Carolina	28401	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
University of Tennessee Cancer Institute-Boston Cancer Group PLC	Memphis	Tennessee	38104	—
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium	Seattle	Washington	98109	—
Multicare Health System	Tacoma	Washington	98415	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00410826, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 9, 2013 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00410826 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →